US equities
|
GOOGL
$324.89
▲+0.00%
GOOG
$321.89
▲+0.00%
MU
$983.23
▲+0.00%
SNDK
$1,404.77
▲+0.00%
SKHY
$164.70
▲+0.00%
LITE
$913.95
▲+0.00%
MSFT
$531.01
▲+0.00%
MRVL
$251.65
▲+0.00%
GOOGL
$324.89
▲+0.00%
GOOG
$321.89
▲+0.00%
MU
$983.23
▲+0.00%
SNDK
$1,404.77
▲+0.00%
SKHY
$164.70
▲+0.00%
LITE
$913.95
▲+0.00%
MSFT
$531.01
▲+0.00%
MRVL
$251.65
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
TNF Pharmaceuticals, Inc. - Common Stock
(NQ:
TNFA
)
5.200
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about TNF Pharmaceuticals, Inc. - Common Stock
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”
September 25, 2025
From
Q/C Technologies, Inc.
Via
Business Wire
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
September 24, 2025
From
Q/C Technologies, Inc.
Via
Business Wire
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 17, 2025
From
TNF Pharmaceuticals Inc.
Via
Business Wire
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 08, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
September 04, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
September 02, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
August 28, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
August 19, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease
June 24, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
May 08, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
April 22, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025
April 16, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
March 17, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
March 05, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
February 25, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
January 29, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
January 15, 2025
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
December 19, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
December 09, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
October 02, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
August 21, 2024
From
TNF Pharmaceuticals, Inc.
Via
Business Wire
